Multiple myeloma: Phase 3 trial results for the oral proteasome inhibitor ixazomib published in the New England Journal of Medicine

Results from the TOURMALINE-MM1 Phase 3 clinical study, published in the New England Journal of Medicine, have shown that oral ixazomib capsules in combination with lenalidomide and dexamethasone… Source link